Prosecution Insights
Last updated: November 18, 2026
Application No. 18/730,610

Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof

Non-Final OA §102§103
Filed
Jul 19, 2024
Priority
Jan 20, 2022 — provisional 63/301,284 +1 more
Examiner
BARRON, SEAN C
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Emory University
OA Round
1 (Non-Final)
53%
Grant Probability
Moderate
1-2
OA Rounds
84%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
327 granted / 622 resolved
-7.4% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
96 currently pending
Career history
733
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, presently claims 1-3, 7, and 10-13, in the reply filed on 8/07/2026. is acknowledged. Claims 4-6, 8, 9, and 14-19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/07/2026. Claims 1-3, 7, and 10-13 are under consideration on the merits. Duplicate Claims Applicant is advised that should claim 2 be found allowable, claim 12 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof and vice versa. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Moon et al. (US 2018/0078625; provided in the IDS dated 10/21/2024). Moon teaches a composition comprising an sHDL nanodisc covalently conjugated to a cysteine-terminated tumor antigen (Ag) peptides (the therapeutic agent), zwitterionic phospholipids DMPC and 4% mol DOPE-PDP (with DOPE-PDP being a species of thiol-reactive phospholipid; [0130]), apolipoprotein mimetic peptide 22A (a nanodisc stabilizing peptide), and wherein cysteine-terminated antigen peptides are conjugated to the thiolated phospholipids via a thiol-linked adduct (Example V at [0319]-[0321]), anticipating claims 1 and 7. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-3, 7, and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Moon et al. (US 2018/0078625; provided in the IDS dated 10/21/2024). The teachings of Moon are relied upon as set forth above in rejecting claims 1 and 7 under 35 U.S.C. § 102. Moon further teaches wherein the conjugated sHDL nanodisc has an average diameter of 10.5 ± 0.5 mm ([0321]), reading on claim 3. Moon further teaches the “antigen” maybe be a nucleic acid, oligonucleotide, or polynucleotide ([0100]), reading on claims 2 and 12. So while Moon does not teach a nucleobase polymer antigen in a single embodiment with the sHDL nanodisc composition of Example V, it would have been obvious to a person of ordinary skill in the art before the invention was filed to substitute the peptide antigen of Moon with the nucleic acid, oligonucleotide, or polynucleotide antigen taught by Moon. A person of ordinary skill in the art would have had a reasonable expectation of success to do so and the skilled artisan would have been motivated to do so because Moon expressly considers the substitution; therefore, the different sources of antigens are functional equivalents in the art, and substituting one for the other would have been obvious at the time of the invention. “When a patent ‘simply arranges old elements with each performing the same function it had been known to perform’ and yields no more than one would expect from such an arrangement, the combination is obvious.” See KSR International Co. v. Teleflex Inc., 82 USPQ2d 1385 (U.S. 2007) at 1395-1396, quoting Sakraida v. AG Pro, Inc., 425 U.S. 273 (1976) and In re Fout, 675 F.2d 297, 301 (CCPA 1982) (“Express suggestion to substitute one equivalent for another need not be present to render such substitution obvious”). Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill before the invention was filed. Claim 13 is rejected under 35 U.S.C. 103 as being unpatentable over Moon as applied to claims 1 and 12 above, and further in view of Thrue et al. (US 7,737,264; Reference A). The teachings of Moon are relied upon as set forth above. Moon further teaches conjugating CpG oligonucleotide as an adjuvant to cholesterol to load the sHDL nanodiscs with CpG ([0292] and [0321]), reading in-part on claim 13. Moon further teaches the treatment of cancer ([0266]), reading in-part on claim 13. Regarding claim 13, Moon does not teach nucleic acid SEQ ID NO: 5. Thrue teaches oligonucleotides directed against the hypoxia-inducible factor-1α. (HIF-1α) gene are provided for modulating the expression of HIF-1α (Abstract), for the treatment of cancer (Col. 2, lines 34-40), reading on claim 13. SEQ ID NO: 55 of Thrue is 100% identical to SEQ ID NO: 5 (Table 1 at Col. 29-30), reading on claim 13. Thrue teaches conjugating the antisense oligonucleotides to cholesterol (Col. 15, lines 57-67), reading on claim 13. It would have been obvious to a person of ordinary skill in the art before the invention was filed to substitute the generic nucleic acid antigen of Moon with SEQ ID NO: 55 of Thrue in Moon’s sHDL nanodisc composition. A person of ordinary skill in the art would have had a reasonable expectation of success to do so because both Moon and Thrue are in-part directed towards methods of treating cancer. The skilled artisan would have been motivated to do so because Thrue teaches that SEQ ID NO: 55 is an oligonucleotide directed against the hypoxia-inducible factor-1α. (HIF-1α) gene are provided for modulating the expression of HIF-1α for the treatment of cancer, and so the substitution would predictable improve upon the envisioned methods of treating cancer of Moon with the sHDL nanodisc composition. Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill before the invention was filed. Claims 1, 7, and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Moon et al. (US 2018/0078625; provided in the IDS dated 10/21/2024) in view of Park et al. (Biomaterials (2018) 161, 69-80; Reference U). The teachings of Moon are relied upon as set forth above. Regarding claim 10, Moon does not teach wherein the nanodisc stabilizing peptide comprises a cysteine amino acid Park teaches HDL nanodisc compositions comprising SP peptide having an N-terminal cysteine which increases the half-life of the composition by about 3215-fold ex vivo and by about 1060-fold in vivo (Abstract and subheading 2.1), reading on claim 10. It would have been obvious to a person of ordinary skill in the art before the invention was filed to substitute the apolipoprotein mimetic peptide 22A of Moon with the cysteine-modified SP peptide of Park in Moon’s sHDL nanodisc composition. A person of ordinary skill in the art would have had a reasonable expectation of success to do so because both Moon and Park are directed towards HDL nanodisc compositions The skilled artisan would have been motivated to do so because Park teaches the substitution would be predictably advantageous to improve the half-life of HDL nanodisc compositions ex vivo and in vivo, and would thus improve upon the composition of Moon. Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill before the invention was filed. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Moon is considered the closest prior art to claim 11, with apolipoprotein mimetic peptide 22A being SEQ ID NO: 4 of Moon (see Fig. 13a) and being about 88% identical to instant SEQ ID NO: 2. However, there would be no motivation from Moon alone or in-combination with Thrue or Park to add a glycine-glycine-cysteine trimer (i.e. GGC) to the C-terminus of the apolipoprotein mimetic peptide 22A of Moon without the benefit of impermissible hindsight reasoning. See M.P.E.P. § 2142. Conclusion Claims 1-3, 7, 10, 12, and 13 are rejected. Claim 11 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN C BARRON whose telephone number is (571)270-5111. The examiner can normally be reached 7:30am-3:30pm EDT/EST (M-F). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached at 571-272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Sean C. Barron/Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Jul 19, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779091
IN SITU EXPANSION OF ENGINEERED DEVICES FOR REGENERATION
2y 8m to grant Granted Nov 03, 2026
Patent 12758622
CHITINASE ADMINISTRATION TO THE AIRWAY TO TREAT INFLAMMATION AND AGE-RELATED PULMONARY FIBROSIS
7y 0m to grant Granted Oct 13, 2026
Patent 12753384
METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL & PROLIFERATION OF ENDOTHELIAL CELLS & STIMULATING ANGIOGENESIS
2y 8m to grant Granted Oct 06, 2026
Patent 12680089
ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
3y 7m to grant Granted Jul 14, 2026
Patent 12644086
ROLLED SCAFFOLD FOR LARGE SCALE CELL CULTURE IN MONOLAYER
5y 10m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
53%
Grant Probability
84%
With Interview (+30.9%)
Low
PTA Risk
Based on 622 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month